Crossmark

Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study

Crossref DOI link: https://doi.org/10.1245/s10434-022-11503-6

Published Online: 2022-03-16

Published Print: 2022-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ushida, Yuta

Inoue, Yosuke

Oba, Atsushi

Mie, Takafumi

Ito, Hiromichi

Ono, Yoshihiro

Sato, Takafumi

Ozaka, Masato

Sasaki, Takashi

Saiura, Akio

Sasahira, Naoki

Takahashi, Yu
License Information

Text and Data Mining valid from 2022-03-16

Version of Record valid from 2022-03-16
More Information

Article History

Received: 1 September 2021

Accepted: 7 February 2022

First Online: 16 March 2022

Disclosures

: Masato Ozaka received honoraria from Taiho Pharmaceutical Co., Ltd. and Yakult Honsha Co., Ltd. Takashi Sasaki received honoraria from Taiho Pharmaceutical Co., Ltd. and Yakult Honsha Co., Ltd. Naoki Sasahira received honoraria from Taiho Pharmaceutical Co., Ltd. The remaining authors declare no conflicts of interest. No funding was received for this study.

Document is current

Any future updates will be listed below